Keloid showdown: which injection flattens scars best?
NCT ID NCT07420166
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two injected treatments for keloid scars: triamcinolone acetonide (a steroid) and verapamil hydrochloride (a blood pressure drug). Sixty adults with keloids received injections every three weeks for up to eight sessions. The goal was to see which treatment better flattened and improved the scar's appearance.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- triamcinolone acetonide and verapamil hydrochloride
- What this could lead to
- If one treatment works better, it could offer a more effective option for flattening keloid scars.
- What could go wrong
- This is a small, completed study with only 60 people. Results may not apply to everyone, and both treatments have possible side effects like pain or skin changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Either gender * Aged between 20 and 60 years * With keloids * Benign dermal growths * Scar length not exceeding 5 centimeters * Keloid duration of five years or less * A baseline Vancouver Scar Scale score of 5 or more Exclusion Criteria: * Pregnant or lactating women * A family history of keloids * Diagnosed with conditions such as acromegaly, diabetes mellitus, or congestive cardiac disease * a history of thyroidectomy * Current or recent use of isotretinoin or anabolic steroids, as determined by history, physical examination, blood glucose analysis, and electrocardiography
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KELOID are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bahawal Victoria Hospital/Quaid-e-Azam Medical College
Bahawalpur, Punjab Province, 63100, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an asthma drug tame stubborn keloid scars?
- Sound waves and herbs take on 'Non-Killing Cancer' of keloid scars
- Do future doctors know the skin risks of tattoos and piercings?
- New PET scan tracer could spot keloids without a biopsy
- Can a simple ointment before surgery lead to better scars?
- Plasma zaps scars: new device aims to smooth skin